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ABSTRACT 
The present investigation concerned with formulation design and evaluation of oral sustained release matrix tablets of Didanosine (DDI) prepared by direct compression method 
using various proportion of release retarding polymer viz; HPMC K100. The prepared tablets were evaluated for weight variation, percentage friability, hardness and in vitro 
dissolution studies and all the formulations showed compliance with pharmacopeia standards. In vitro release studies were performed using USP type II apparatus (Paddle type) 
at 50 rpm. Formulation F1 released around 35% of drug after 1 hour and the cumulative percentage of drug release is not more than 85% at the end of 12 hour in formulation F4. 
The formulations F2 and F3 sustained release of drug for 12 hrs with 31.39%, and 23.54% release of drug after 1hr and more than 90% at the end of 12 hrs. The release kinetics 
was analyzed using Zero-order model equation, Higuchi’s square root equation and Korsmeyer and Peppas’ empirical equation. The regression coefficient obtained for first 
order kinetics were found to be higher (R
2: 0.978 to 0.994) when compared with those of the zero order kinetics (R
2: 0.395 to 0.786), indicating that drug release from all 
formulations followed first order kinetics. The mechanism of drug release from formulation F1 and F2 showed behavior of Fickian diffusion and remaining formulations showed 
non-Fickian diffusion. 
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INTRODUCTION 
Sustained-release  oral  delivery  systems  achieve  therapeutically 
effective concentrations of drug in the systemic circulation over an 
extended period of time, which provides better patient compliance 
and allowing a reduction of both the total dose of drug administered 
and  the  incidence  of  adverse  side  effects.  Among  the  different 
approaches, matrix systems still appear as one of the most attractive 
from the economic as well as the process development and scale-up 
points of view. Didanosine acts by inhibiting reverse-transcriptase, 
an enzyme required for replication of the human immunodeﬁciency 
virus  (HIV),  and  by  blocking  viral  DNA  synthesis,  thus  causing 
termination of the DNA molecular chain. Didanosine treatment was 
found to be a useful and effective alternative in patients who did not 
tolerate or not respond to Zidovudine, the mainstay of anti-HIV-1 
drugs.  Didanosine  has  lower  and  more  highly  variable 
bioavailability  in  comparison  with  other  nucleoside  reverse 
transcriptase inhibitors. In the gastric medium it is rapidly degraded 
due  to  acid  hydrolysis.  Such  a  problem,  together  with  need  for 
repetitive dosing, low plasma proteins binding (  5%), brief plasma 
elimination half-life (30 min–4h), dose-related toxicity, in addition 
to a relatively low daily dosage (250–400 mg), make this drug a 
suitable  candidate  for  incorporating  into  oral  prolonged-release 
dosage  forms
1.  HIV  (Human  Immunodeficiency  Virus)  is  a  virus 
which  causes  AIDS  (Acquired  Immuno  Deficiency  Syndrome)  in 
which  a  portion  is  affected  by  a  series  of  diseases  due  to  poor 
immunity
  2.  Didanosine  (DDI)  is  a  nucleoside  analog  reverse 
transcriptase  inhibitor  used  in  AIDS  treatment  to  suppress  HIV 
replication.  DDI  can  be  considered  a  suitable  candidate  for 
sustained-release formulations from both the biopharmaceutical and 
pharmacokinetic points of view 
3. 
MATERIALS AND METHODS  
Didanosine  was  obtained  as  a  gift  sample  from  Aurobindo 
Pharmaceutical Pvt. Ltd, Hyderabad. HPMC K100 was obtained from 
Dr Reddy’s Lab (Hyderabad, India), Micro Crystalline Cellulose and 
Mg. Stearate from Loba Chem (Mumbai, India). All other chemicals 
and ingredients were used for study are of commercial grade. 
Methods 
Matrix  embedded  controlled  release  tablets  of  Didanosine  were 
prepared  by  direct  compression  technique  using  various 
concentrations  of  HPMC  K100.  All  ingredients  except  magnesium 
stearate and aerosil were blended in glass mortar uniformly. After 
the  sufficient  mixing  of  drug  as  well  as  other  components, 
magnesium stearate and aerosil were added and mixed for additional 
5  minutes  and  finally  compressed  on  a  rotary  tableting  machine 
using 7.96-mm punches. 
Evaluation of Matrix Tablets
  
Physical Characterization of the Designed Tablet 
The properties of the compressed matrix tablets, such as hardness, 
friability,  weight  variation,  and  content  uniformity  were 
determined  using  reported  procedure.  Tablet  hardness  was 
determined for 10 tablets using a Monsanto tablet hardness tester. 
Friability  was      determined  by  testing  10  tablets  in  a  Roche 
friability  tester  for  4  min  at  25  rpm.  The  weight  variation  was 
determined  by  taking  weight  of  20  tablets  using  an  electronic 
balance (Sartorius Electronic Balance, BT-2245). The drug content 
of  the  manufactured  tablets  of  each  batch  was  determined  in 
triplicate. For each batch 10 tablets were taken, weighed and finely 
powdered.  An  accurately  weighed  quantity  of  this  powder  was 
taken and suitably dissolved and analyzed after making appropriate 
dilutions
4, 5. 
In Vitro Drug Release Studies 
Release rate of all the designed formulations were studied up to 12 
hours using USP- type II (Paddle) dissolution apparatus at 50 rpm. 
The dissolution medium (900ml) consisted of phosphate buffer p
H 
7.4 maintained at 37°C ± 0.5°C. Sample of 5 ml was withdrawn at 
specific time intervals throughout the dissolution study of 12 hours 
for  analysis  and  replaced  with  fresh  dissolution  medium.  After 
appropriate  dilution  the  samples  were  analyzed  for  Didanosine 
using  a  double  beam  UV-Visible  spectrophotometer  at  249nm 
using pH 7.4 phosphate buffer. The release studies were conducted 
in triplicate. 
Kinetic analysis of given data  
Zero order kinetics 
Drug  dissolution  from  pharmaceutical  dosage  forms  that  do  not 
disaggregate and release the drug slowly (assuming that area does 
not  change  and  no  equilibrium  conditions  are  obtained)  can  be 
represented by the following equation:  
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Where W0 is the initial amount of drug in the pharmaceutical dosage 
form, Wt is the amount of drug in the pharmaceutical dosage form at 
time t and K0 is proportionality constant. Dividing this equation by 
W0 and simplifying: 
ft = K0t 
Where ft = 1- (wt/ w0) and ft represents the fraction of drug dissolved 
in time t and k0 the apparent dissolution rate constant or zero order 
release constant. 
First order kinetics 
The relation expressing this model: 
     Log Qt=Log Q0+K1t/2.303 
Where  Qt  is  the  amount  of  drug  released  in  time  t,  Q0  is  initial 
amount of drug in the solution and K1 is the first order release rate 
constant. 
Korsmeyer Peppas model 
It can be represented by the following equation:  
  Qt/Q∞ = Kkt
n 
Where  Kk  is  a  constant  incorporating  structural  and  geometric 
characteristic of the drug dosage form and n is the release exponent, 
indicative of the drug release mechanism. For matrix tablets, an n 
value of ~0.5 indicates diffusion-controlled mechanism while an n 
value  of  ~1.0  indicates  erosion-controlled  release.  Intermediate 
values suggest dual mechanism of both diffusion and erosion.  
Higuchi Model 
It can be represented by the following equation: 
  Qt = KHt
1/2 
Where   Qt = the amount of drug released at time t and  
  KH= the Higuchi release rate;
 6, 7, 8 
RESULTS AND DISCUSSION 
The  oral  sustained  release  matrix  tablets  of  Didanosine  were 
formulated by using HPMC K100 as the retardant polymers. Matrix 
tablets were prepared by direct compression method and prepared 
tablets  were  evaluated  for  weight  variation,  percentage  friability, 
hardness  and  in  vitro  dissolution  studies.  All  the  formulations 
showed  compliance with pharmacopeia standards. In vitro release 
studies  revealed  that  the  release  rate  decreased  with  increase 
polymer proportion of HPMC K100. Formulation F1 released around 
35% of drug after 1 hour and the cumulative percentage of drug 
release is not more than 85% at the end of 12 hour in formulation F4. 
The formulations F2, and F3 sustained release of drug for 12 hrs with 
31.39%, and 23.54% release of drug respectively after 1hr and more 
than 90% at the end of 12 hrs. It can be concluded that a stable 
formulation  can  be  developed  by  incorporating  in  a  definite 
proportion  of  HPMC  K100,  So  that  sustained  released  profile  is 
maintained for an extended periods of time. Further the release data 
was fitted to various mathematical models to evaluate the kinetics 
and mechanism of drug release. The regression coefficient obtained 
for first order kinetics were found to be higher (R
2: 0.978 to 0.994) 
when compared with those of the zero order kinetics (R
2: 0.395 to 
0.786), indicating that drug release from all formulations followed 
first order kinetics. In this experiment, the in-vitro release profiles of 
drug from all these formulations can be best expressed by Higuchi 
equation as the plots showed the linearity (R
2: 0.945 to 0.991). To 
confirm  the  diffusion  mechanism  the  data  was  fitted  into 
Korsemeyer-Peppas  equation.  All  the  formulations  showed  good 
linearity  (R
2:  0.965  to  0.991)  with  slope  (n)  values ranging  from 
0.387 to 0.594. The mechanism of drug release from formulations F1 
and  F2  showed  behavior  of  Fickian  diffusion  and  remaining 
formulations showed non-Fickian diffusion. 
CONCLUSION 
It  can  be  concluded  that  stable  formulation  can  be  developed  by 
incorporating  in  a  definite  proportion  of  hydrophilic  release 
retarding  polymer  like  HPMC  K100,  So  that  sustained  released 
profile is maintained for an extended periods of time. 
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Table 1: Preparation of Matrix Tablets of Didanosine 
Formulation 
ingredients 
Formulation batch 
F1  F2  F3  F4 
Didanosine(mg)  50  50  50  50 
HPMC K100(mg) 
(10%) 
30 
(15%) 
45 
(20%) 
60 
(25%) 
75 
MCC(mg)  214  199  184  169 
Aerosil(mg)  3  3  3  3 
Magnesium stearate (mg)  3  3  3  3 
Total wt(mg)  300  300  300  300 
 
Table 2: Physical Characterization of Prepared Matrix Tablets of Didanosine 
Formulation 
batch 
Avg. Wt. 
(mg) 
Hardness 
(kg/cm
2 ) 
Drug 
Content (%) 
Friability 
(%) 
F1  296.25±6.257  5.12±0.337  97.292±2.282  0.587 
 
F2  307.79±6.63  5.23±0.288  97.654±2.246  0.571 
 
F3  307.79±6.63  5.08±0.265  97.932±2.064  0.582 
 
F4  303.55±6.634  5.16±0.188  99.051±2.102  0.566 
 
 
Values are represented as mean ± S.D. (n = 3) 
 
Table 3: Release Exponent and Drug transport mechanism 
Release exponent (n)  Drug transport mechanism 
0.5  Fickian diffusion 
0.5<n<1.0  Anomalous transport 
1.0  Case-II transport 
Higher than 1.0  Super Case-II transport 
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Table 4: Kinetic analysis of Dissolution Profile from Batches F1 to F4 
Models    F1  F2  F3  F4 
Peppas Model 
n  0.387  0.426  0.546  0.594 
R
2  0.974  0.981  0.991  0.965 
K1  37.84  33.72  24.60  19.05 
Higuchi Model 
R
2  0.945  0.969  0.991 
0.987 
 
 
  K2  30.04  28.93  26.98  22.89 
Zero- Order 
R
2  0.395  0.508  0.786  0.774 
K3  10.04  9.70  9.18  7.78 
First- Order 
R
2  0.980  0.994  0.978  0.979 
K4  0.216  0.193  0.202  0.119 
 
 
 
Fig.1: In-vitro drug release profile of sustained release matrix tablets of Didanosine Using HPMC K100 
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